Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BTAI logo BTAI
Upturn stock ratingUpturn stock rating
BTAI logo

BioXcel Therapeutics Inc (BTAI)

Upturn stock ratingUpturn stock rating
$2.99
Last Close (24-hour delay)
Profit since last BUY-56.03%
upturn advisory
WEAK BUY
BUY since 25 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/16/2025: BTAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $19.8

1 Year Target Price $19.8

Analysts Price Target For last 52 week
$19.8 Target price
52w Low $1.17
Current$2.99
52w High $13.28

Analysis of Past Performance

Type Stock
Historic Profit -92.16%
Avg. Invested days 16
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/16/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 50.75M USD
Price to earnings Ratio -
1Y Target Price 19.8
Price to earnings Ratio -
1Y Target Price 19.8
Volume (30-day avg) 3
Beta 0.21
52 Weeks Range 1.17 - 13.28
Updated Date 09/15/2025
52 Weeks Range 1.17 - 13.28
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -12.13

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -13210%

Management Effectiveness

Return on Assets (TTM) -68.72%
Return on Equity (TTM) -1766.94%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 141294375
Price to Sales(TTM) 58.47
Enterprise Value 141294375
Price to Sales(TTM) 58.47
Enterprise Value to Revenue 162.78
Enterprise Value to EBITDA -0.75
Shares Outstanding 16009100
Shares Floating 14009846
Shares Outstanding 16009100
Shares Floating 14009846
Percent Insiders 3.8
Percent Institutions 6.23

ai summary icon Upturn AI SWOT

BioXcel Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

BioXcel Therapeutics Inc. was founded in 2010. Initially focused on drug repurposing using artificial intelligence, it has evolved into a biopharmaceutical company developing treatments for neuroscience and immuno-oncology disorders.

business area logo Core Business Areas

  • Neuroscience: Development and commercialization of therapies for acute agitation associated with schizophrenia or bipolar I or II disorder, and other neurological conditions.
  • Immuno-oncology: Research and development of therapies for cancer through modulation of the immune system, although this area is currently less emphasized.

leadership logo Leadership and Structure

The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments for research and development, clinical operations, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • BXCL501 (DEXMEDETOMIDINE): A sublingual film formulation of dexmedetomidine, marketed as Igalmi, approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. While approved, uptake has been slower than expected, impacting revenue. The competitors are antipsychotics (oral and injectable) and benzodiazepines, which are mainstays of treatment for acute agitation. Exact market share data is unavailable due to the novel nature of the product and limited commercial history, although BXCL501 represents a relatively small portion of the overall market for agitation treatment.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and regulated, with significant research and development costs. The neuroscience market is growing due to increasing prevalence of mental health disorders and the development of new treatments.

Positioning

BioXcel Therapeutics is positioned as an innovator in the neuroscience space with its AI-driven drug development approach and novel sublingual formulation of dexmedetomidine. Its competitive advantage lies in its potentially faster onset of action and non-invasive administration compared to traditional treatments.

Total Addressable Market (TAM)

The market for acute agitation treatment is estimated to be substantial, potentially exceeding $1 billion annually. BioXcel is positioned to capture a portion of this TAM with Igalmi, though its actual market penetration remains to be seen.

Upturn SWOT Analysis

Strengths

  • Novel sublingual formulation of dexmedetomidine (Igalmi)
  • AI-driven drug development platform
  • Focus on unmet needs in neuroscience
  • FDA approval for Igalmi

Weaknesses

  • Limited commercial history
  • Dependence on a single approved product (Igalmi)
  • High cash burn rate
  • Uncertainty about market adoption of Igalmi
  • Limited Sales

Opportunities

  • Expansion of Igalmi's label to other indications (e.g., agitation in dementia)
  • Development of new products through its AI platform
  • Partnerships with larger pharmaceutical companies
  • Further Clinical trials to validate drug effectiveness.

Threats

  • Competition from existing treatments (antipsychotics, benzodiazepines)
  • Regulatory risks
  • Reimbursement challenges
  • Potential safety concerns
  • Negative clinical trial results

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • ABBV
  • OTSK

Competitive Landscape

BioXcel Therapeutics faces competition from established pharmaceutical companies with broader product portfolios and greater financial resources. Its competitive advantage lies in its novel approach to drug development and its focus on specific unmet needs.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily driven by research and development milestones and regulatory approvals.

Future Projections: Future growth is dependent on the commercial success of Igalmi and the development of new products. Analyst estimates vary widely due to uncertainty regarding market adoption.

Recent Initiatives: Recent initiatives include expanding the sales force for Igalmi and conducting clinical trials to evaluate its efficacy in additional indications.

Summary

BioXcel Therapeutics is a biopharmaceutical company focused on neuroscience and utilizing AI for drug development. Their primary asset is Igalmi, which is approved for acute agitation. The company faces challenges related to commercialization and competition. Future success hinges on Igalmi's market adoption and pipeline development, along with strategic partnerships, and prudent management of cash resources.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company reports
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial projections are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioXcel Therapeutics Inc

Exchange NASDAQ
Headquaters New Haven, CT, United States
IPO Launch date 2018-03-08
Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 37
Full time employees 37

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.